Clozapine Shows Better Results in Schizoaffective Disorder
A real-world trial showed that in adults with dual psychosis, clozapine was effective in alleviating psychotic and affective symptoms, with better outcomes being observed in schizoaffective disorder (SZD) than in treatment-resistant schizophrenia (TRS).
METHODOLOGY:
Researchers conducted a prospective, pragmatic clinical trial from 2021 to 2024 in Spain and included 127 participants with refractory psychosis (mean age, 38.5 years; 74.8% men).
Participants were divided into three arms: those with TRS receiving clozapine (TRS-clozapine; n = 43), those with TRS receiving optimised standard antipsychotics (TRS-control; n = 42), and those with SZD receiving clozapine (SZD-clozapine; n = 42; non-randomised due to low prevalence).
Monthly assessments over 3 months included the use of the Positive and Negative Syndrome Scale (PANSS), Young Mania Rating Scale (YMRS), Montgomery-Åsberg Depression Rating Scale (MADRS), Calgary Depression Scale for Schizophrenia (CDSS), Clinical Global Impression (CGI) scale, and Udvalg für Kliniske Undersogelser (UKU) scale.
Researchers evaluated the efficacy of clozapine in patients with TRS, the effect of clozapine on real-world SZD psychotic and affective symptoms, and the response and tolerability to clozapine in patients with TRS vs SZD.
TAKEAWAY:
Compared with the TRS-control group, the TRS-clozapine group had greater 3-month reductions in PANSS positive, negative, and total (P/N/T) scores (P < .001 for all) and CDSS (P < .001), CGI (P < .001), and MADRS (P = .003) scores, whereas the SZD-clozapine group showed rapid, significant improvements in psychotic scale scores (PANSS-P, P = .027; PANSS-N, P = .002; and PANSS-T, P = .005) and YMRS, MADRS, and CDSS scores (P < .001 for all) from month 1 to month 3.
The SZD-clozapine group showed greater reductions in the following scores than the TRS‐clozapine group at 3 months: PANSS-P (-23.4 vs -19.3), PANSS-T (-68.7 vs -63.0), YMRS (-15.3 vs -4.9), MADRS (-8.4 vs -6.0), and CDSS (-5.4 vs -4.1).
Patients receiving clozapine reported better subjective treatment perception (P < .01) and required fewer adjunct antipsychotics and sedatives, and clozapine emerged as the sole independent predictor of superior symptom and substance use outcomes.
Clozapine was well tolerated in both groups, with no serious treatment-related adverse events. Mild drowsiness or asthenia was observed, which was managed by lowering co-medication doses. UKU side effect scores also reduced from month 2 onwards.
IN PRACTICE:
"[The study] findings have direct clinical implications, reinforcing the evidence supporting the use of CLZ [clozapine] in dual psychosis and expanding therapeutic options for SZD," the authors wrote. "Moving forward, efforts to improve clozapine use should focus on enhancing clinician education, standardising knowledge sources and promoting best practices in its management. Additionally, the development of well-designed long-term studies will be essential," they added.
SOURCE:
This study was led by Marc Peraire, Consorci Hospitalari Provincial de Castelló, Castellón de la Plana, Spain. It was published online on August 1 in the Journal of Psychopharmacology.
LIMITATIONS:
This study was limited by incomplete patient histories and the absence of antisuicidal efficacy measures. Additional constraints were the lack of comparison between dual-disorder and pure psychosis cohorts, unstable diagnostic labels, gender imbalance, a single-site design, potential overfitting in regression models, and a relatively short follow-up period.
DISCLOSURES:
This study received financial support from the Research Foundation of the Provincial Hospital of Castellón. The authors reported having no conflicts of interest.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
3 minutes ago
- Medscape
Do Designated Pharmacists Make Cancer Care Safer?
TOPLINE: Adding a designated pharmacist to hematology-oncology teams reduced adverse drug reaction (ADR) rates by 62% (age-adjusted hazard ratio [AHR], 0.38). The pharmacist made 588 recommendations with a 95% implementation rate, identifying 287 medication errors. METHODOLOGY: A parallel randomized clinical trial conducted from July 2020 to October 2022 included 182 patients randomly assigned in a 1:1 ratio to receive comprehensive pharmacist intervention or standard care. Participants were monitored over a 4-month intervention period and 1 month afterward, with the pharmacist evaluating treatments, providing medication counseling, and making recommendations to physicians in the intervention group. Research took place in the hematology-oncology unit of a medical center owned by Clalit Health Services, with two outpatient clinics staffed by 8 hematology-oncologists, 10 nurses, 1 social worker, and 1 half-time pharmacist. Unrelated pharmacologist physicians determined which recommendations were medication errors and assessed their severity levels using the Harm Associated with Medication Error Classification. TAKEAWAY: The intervention group demonstrated lower ADR rates (AHR, 0.38; 95% CI, 0.23-0.65; P < .001) for at least one ADR and (AHR, 0.25; 95% CI, 0.09-0.67; P = .006) for at least one moderate or severe ADR. The designated pharmacist made 588 recommendations for the intervention group, with a 95% implementation rate, identifying 287 as medication errors. Analysis revealed higher detection of administration errors (incidence rate ratio, 2.61; 95% CI, 1.38-4.92; P = .003) and a higher proportion of potentially serious medication errors (P = .003) in the intervention group. Integration of an oncology pharmacist into hematology-oncology clinics reduced ADRs and improved the detection and prevention of potentially serious medication errors. IN PRACTICE: 'Incorporating oncology-trained pharmacists into hematology-oncology care teams is an effective strategy for reducing ADR rates and enhancing medication safety,' wrote the authors of the study. SOURCE: The study was led by Areen Khateeb Alabbasi, PhD, School of Public Health, University of Haifa in Haifa, Israel. It was published online in JCO Oncology Practice. LIMITATIONS: The single-center design and focus on hematologic malignancies may limit the generalizability of the findings. Information bias could have affected ADR assessments, as only physician-documented cases were included. The sample size limited statistical power for identifying significant differences in some secondary outcomes, such as emergency department visits and hospitalizations. The study did not include patient-reported outcomes or clinician feedback. Additionally, no financial information was provided to assess the cost-effectiveness of the model. DISCLOSURES: Naama Schwartz reported being employed by Medtronic and serving as a lecturer at the University of Haifa, School of Public Health. Schwartz also disclosed being the CEO of Hepacure Pharma, an early-stage biotech company established in September 2024 that develops peptides for fatty liver diseases. Shmuel Klang reported serving in consulting or advisory roles for Novo Nordisk and Novartis. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
31 minutes ago
- Yahoo
Newron Begins Enrollment in Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-Resistant Schizophrenia (TRS)
Ad hoc announcement pursuant to Art. 53 LR ENIGMA-TRS 1 is an international, one-year, double-blind, placebo-controlled Phase III study in at least 600 patients; 12-week study results expected in Q4 2026 Evenamide, a first-in-class glutamate modulator, has the potential to be the first add-on therapy for TRS patients and for poorly responding patients with schizophrenia Unique glutamatergic modulation mechanism of action offers new therapeutic option for this patient population MILAN & MORRISTOWN, N.J., August 12, 2025--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that following the completion of a 42 day-screening period and the review of the patients by the Independent Eligibility Committee, it has successfully randomized the first patients in its pivotal ENIGMA-TRS 1 Phase III development program. ENIGMA-TRS 1 will evaluate evenamide as an add-on therapy to current antipsychotics, including clozapine, in patients with treatment-resistant schizophrenia (TRS). "Today's announcement marks an important milestone for the clinical advancement of evenamide for treatment-resistant schizophrenia patients who urgently need more effective therapeutic options," said Ravi Anand, CMO, Newron Pharmaceuticals. "We look forward to advancing evenamide through this pivotal Phase III study and delivering an important benefit to patients in need." ENIGMA-TRS 1 is an international, 52-week, randomized, double-blind, placebo-controlled Phase III study evaluating the efficacy, tolerability, and safety of the 15mg BID and 30mg BID therapeutic doses of evenamide compared to placebo. Patients on second-generation antipsychotics (SGAs), including clozapine, need to meet Treatment Response and Resistance Psychosis (TRRIP) international consensus criteria for TRS. ENIGMA-TRS 1 will enroll at least 600 patients at study centers in Europe, Asia, Latin America and Canada. Prior to randomization, patients undergo a 42-day screening period, during which their TRS diagnosis, antipsychotic plasma levels (background medication), and conformance to protocol selection criteria will be evaluated by an Independent Eligibility Assessment Committee (IEAC) of three leading international schizophrenia experts. The primary assessment of efficacy and safety will be performed 12 weeks after randomization to treatment. The study will continue double-blind and placebo-controlled until the 52-week time point. The 12-week results from the study are expected in Q4 2026. Results from previous Phase II (study 014/015) and Phase III (study 008A) studies have demonstrated evenamide's significant and increasing efficacy as an add-on therapy on multiple measures of psychopathology in patients with TRS and inadequate responders, respectively. These results also confirmed a favorable safety and tolerability profile, adding to the growing evidence that evenamide's glutamatergic inhibition mechanism of action offers an innovative therapeutic option to schizophrenia patients who are not benefiting from current antipsychotic treatments. ENIGMA-TRS 2, the second study of Newron's pivotal Phase III ENIGMA-TRS program, has been approved by the US Food and Drug Administration (FDA), and will be performed at centers in the US and selected additional countries. It will include at least 400 patients in a 12-week, randomized, double-blind, placebo-controlled Phase III study, designed to evaluate the efficacy, tolerability, and safety of the 15mg BID dose of evenamide. Patients will meet selection criteria and be reviewed by the above-mentioned IEAC. The analysis for determination of efficacy and safety will be performed after patients complete 12 weeks of participation in the trial. US investigational centers are expected to initiate the study by October 2025. About schizophrenia Approximately 25 million people worldwide are affected by schizophrenia. Despite more than 60 different types of atypical and typical antipsychotics used to treat schizophrenia globally, a considerable number of patients remain severely ill or resistant to treatment. Overall, 30-50% of patients do not respond to the available medications and are defined as treatment resistant. In addition to the patients with treatment-resistant schizophrenia (TRS), another 20-30% are described as "poor responders to antipsychotic medication", even if not meeting the criteria for TRS. New findings indicate that patients with TRS have abnormalities in the glutamatergic system, but not in dopaminergic transmission, so there is a significant unmet medical need for treatments with a glutamatergic mechanism of action, efficacious both in TRS patients and in those who are poor responders to the current treatments. About evenamide Evenamide is the first new chemical entity that has demonstrated significant benefits in this difficult-to-treat patient population, as seen in the potentially pivotal Phase III study 008A trial, as an add-on treatment to second generation antipsychotics including clozapine, in 291 poorly responding patients with chronic schizophrenia. The primary endpoint, the Positive and Negative Syndrome Scale (PANSS)1, and the key secondary endpoint, the Clinical Global Impressions Scale – Severity (CGI-S), were met and showed statistical significance compared to placebo. Importantly, evenamide treatment was associated with statistically significant increases in the proportion of patients who experienced "clinically meaningful benefit" on the outcome variables. Evenamide was extremely well tolerated, without any of the usual side effects of available antipsychotics. About Newron Pharmaceuticals Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on developing novel therapies for patients with diseases of the central and peripheral nervous system. Headquartered in Bresso, near Milan, Italy, Newron is advancing its lead compound, evenamide, a first-in-class glutamate modulator, which has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently in Phase III development and clinical trial results to date demonstrate the benefits of this drug candidate in the TRS patient population, with significant improvements across key efficacy measures increasing over time, as well as a favourable safety profile, which is uncommon for available antipsychotic medications. Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. Newron has a proven track record in bringing CNS therapies to market. Its Parkinson's disease treatment, Xadago® (safinamide), is approved in over 20 markets, including the USA, UK, EU, Switzerland, and Japan, and commercialized in partnerships with Zambon and Meiji Seika. For more information, please visit: Important Notices This document contains forward-looking statements, including (without limitation) about (1) Newron's ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement of various clinical trials and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron's financial resources, and (4) assumptions underlying any such statements. In some cases, these statements and assumptions can be identified by the fact that they use words such as "will", "anticipate", "estimate", "expect", "project", "intend", "plan", "believe", "target", and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron's strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation difficulties in enrolling clinical trials, negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron's research programs, development activities, commercialization plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly update or revise forward-looking statements except as may be required by applicable regulations of the SIX Swiss Exchange or the Dusseldorf Stock Exchange where the shares of Newron are listed. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. 1 Positive and Negative Syndrome Scale (PANSS) is widely used in clinical trials of schizophrenia and is considered the "gold standard" for assessment of antipsychotic treatment efficacy (Innvo Clin Neurosci, 2017: View source version on Contacts For more information, please contact: Newron Stefan Weber – CEO; +39 02 6103 46 26, pr@ UK/Europe Simon Conway / Ciara Martin / Natalie Garland-Collins, FTI Consulting; +44 20 3727 1000, SCnewron@ Switzerland Valentin Handschin, IRF; +41 43 244 81 54, handschin@ Germany/Europe Anne Hennecke / Maximilian Schur, MC Services; +49 211 52925227, newron@ USA Paul Sagan, LaVoieHealthScience; +1 617 865 0041, psagan@ Sign in to access your portfolio
Yahoo
31 minutes ago
- Yahoo
Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda
The Global Multiple Myeloma Market is projected to grow from USD 21.78 billion in 2024 to USD 40.41 billion by 2033, at a CAGR of 7.11%. Growth drivers include rising multiple myeloma cases, advances in targeted therapies like monoclonal antibodies, and the increasing adoption of immunotherapies. Enhanced diagnostics and greater healthcare accessibility are boosting market expansion. Key regions such as the U.S., Europe, and Asia-Pacific, are witnessing heightened therapy adoption. Challenges include high therapy costs and resistance to current treatments. Major players investing in R&D include Novartis, Abbvie, and Bristol-Myers Squibb. Key terms: Global Multiple Myeloma Market, Multiple Myeloma Growth, Targeted Therapies, Immunotherapies, Market Expansion. Multiple Myeloma Market Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "Multiple Myeloma Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to Global Multiple Myeloma Market was valued at USD 21.78 billion in 2024 and is expected to reach USD 40.41 billion by the year 2033, at a CAGR of 7.11% during the forecast period from 2025 to 2033 The growth of the market is fueled by the increasing number of multiple myeloma cases, developments in targeted therapies, and the expanding use of immunotherapies. Increased oncology research, enhanced diagnostic methodologies, and the increasing availability of healthcare facilities are further adding to market growth. The therapies for multiple myeloma are chemotherapy, immunotherapy, target therapies, corticosteroids, and stem cell transplants. Increasing advancements in monoclonal antibodies and CAR-T cell therapy are enhancing outcomes among patients, and these therapies are becoming more popular globally. With increasing awareness of cancer and better diagnosis methods, multiple myeloma therapies are becoming increasingly popular in the U.S., Europe, and Asia-Pacific. Pharmaceutical industries are heavily investing in new drug development, and governments are also funding cancer research, further propelling treatment availability. Consequently, the multiple myeloma market continues to grow, bringing new hope to patients of Growth in the Multiple Myeloma Market Improvements in Targeted TherapiesThe emergence of targeted therapies like monoclonal antibodies and proteasome inhibitors has considerably enhanced treatment efficacy for multiple myeloma patients. These treatments have greater efficacy with less side effect than conventional chemotherapy. With continued research in immunotherapy and CAR-T cell therapy, more effective therapies are being made available, and patient survival is on the rise. Consequently, drug companies are investing heavily in drug development, further fueling market growth. Dec 2024, Merck reported that the FDA has accepted for filing the Biologics License Application for clesrovimab (MK-1654), a long-acting monoclonal antibody to help protect infants from RSV in their first RSV Prevalence of Multiple MyelomaThe worldwide prevalence of multiple myeloma is on the rise, especially among the elderly. Genetic susceptibility, exposure to toxic chemicals, and lifestyle changes are factors that lead to an increased incidence of the disease. As more and more cases are being diagnosed yearly, the need for effective treatment options is on the rise. This has driven governments and health organizations to invest more in multiple myeloma research and the availability of treatments, driving market growth. There were about 35,000 cases of MM in 2021 globally, with the most in China and Germany, with 47,003 and 32,010 cases, respectively. In 2021, Europe boasted the highest ASIR and ASPR, and North America the highest ASMR and Healthcare Spending and AwarenessRising healthcare spending in developed and emerging economies is contributing positively towards the multiple myeloma market. Governments and private bodies are initiating awareness campaigns and screening programs to encourage early detection and timely treatment. Patients now enjoy improved access to new therapies through reimbursement schemes and insurance coverage, also driving the adoption of treatments. With increasing numbers of hospitals and clinics incorporating advanced oncology treatments, the multiple myeloma market is set to see significant in the Multiple Myeloma Market Exorbitant Cost of TherapyImmunotherapies and targeted agents used in treating multiple myeloma are costly, hence unavailable to most patients, particularly those in developing areas. Bone marrow transplants and maintenance therapy costs further increase the burden. In spite of availability of reimbursement schemes in certain countries, affordability becomes a serious concern, limiting the growth of the Effects and Therapy ResistanceIn spite of the progress in treatment, patients tend to develop resistance to current therapies with time, which requires frequent modification of treatment regimens. Moreover, most therapies have serious side effects, such as infections, tiredness, and organ injury, which lower the quality of life for patients. These issues propel the necessity for ongoing research and innovation in treatment methods. Key Players Analyzed: Overview, Key Persons, Recent Developments, Product Portfolio, Revenue Novartis AG Abbvie Inc. Sanofi Johnson and Johnson Baxter International Inc. Pfizer Inc. Takeda Pharmaceutical Company Ltd Bristol-Myers Squibb Company Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $21.78 Billion Forecasted Market Value (USD) by 2033 $40.41 Billion Compound Annual Growth Rate 7.1% Regions Covered Global Key Topics Covered: 1. Introduction2. Research & Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Global Multiple Myeloma Market6. Market Share Analysis6.1 By Drugs Types6.2 By Disease Types6.3 By End User6.4 By Country7. Drugs Types7.1 Chemotherapy7.2 Protease Inhibitors7.3 Monoclonal Antibody7.4 Others8. Disease Types8.1 Active multiple myeloma8.2 Smoldering multiple myeloma9. End User9.1 Hospitals9.2 Clinics9.3 Others10. Countries10.1 North America10.1.1 United States10.1.2 Canada10.2 Europe10.2.1 France10.2.2 Germany10.2.3 Italy10.2.4 Spain10.2.5 United Kingdom10.2.6 Belgium10.2.7 Netherlands10.2.8 Turkey10.3 Asia-Pacific10.3.1 China10.3.2 Japan10.3.3 India10.3.4 Australia10.3.5 South Korea10.3.6 Thailand10.3.7 Malaysia10.3.8 Indonesia10.3.9 New Zealand10.4 Latin America10.4.1 Brazil10.4.2 Mexico10.4.3 Argentina10.5 Middle East & Africa10.5.1 South Africa10.5.2 Saudi Arabia10.5.3 United Arab Emirates11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Competition11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threats13. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Multiple Myeloma Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
